+41 91 682 20 40 info@elixi-int.com

European Commission Approves Merck’s DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen for the Treatment of HIV-1 in Appropriate Patients

Delstrigo is an antiviral medicine used to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). Delstrigo contains the active substances doravirine, lamivudine and tenofovir disoproxil. The medicine is not…

Read More